News

TransCode Therapeutics Welcomes Dr. Michel Janicot as Senior Advisor

TransCode Therapeutics Welcomes Dr. Michel Janicot as Senior Advisor

TransCode Therapeutics Announces Key Addition to Executive Team

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a pioneering company in the fields of immuno-oncology and targeted cancer therapies, is excited to announce the appointment of Dr. Michel Janicot as its Senior Development Officer. With decades of extensive experience in drug development, Dr. Janicot is set to make a significant impact on the company's mission to combat cancer through innovative RNA technologies.

Expertise and Vision of Dr. Janicot

Dr. Janicot brings over 35 years of pharmaceutical research and clinical development experience, particularly in oncology. His career includes senior roles at renowned organizations, where he led numerous successful drug development programs. As a leader, he is known for his ability to guide strategic initiatives aimed at enhancing R&D capabilities, particularly in the successful translation of research into viable treatment options.

Industry Impact and Ongoing Projects

His initial involvement with TransCode will be part-time, allowing him to incorporate his wealth of knowledge into the company's oncology pipeline. Philippe P. Calais, the CEO of TransCode Therapeutics, noted that Dr. Janicot's vast expertise will bolster the company's ongoing projects, notably TTX-MC138 and Seviprotimut-L. These drug candidates are crucial to addressing the challenges of metastatic and recurrent cancer.

A Pioneer in RNA-Based Therapies

Dr. Janicot holds a Ph.D. in Biochemistry from Université Paris VII in France and has a solid foundation in his field, supported by postdoctoral training at The Johns Hopkins University. His transition into the pharmaceutical industry began with Rhône-Poulenc Rorer, paving the way for a track record of excellence in drug development at leading companies like Janssen Pharmaceutica.

Commitment to Pediatric Oncology

Since founding JMi ONConsulting, Dr. Janicot has been instrumental in guiding biotechnology firms through complex oncology R&D pathways. His commitment extends beyond corporate boundaries, as he also co-founded the aPODD Foundation, which focuses on accelerating the development of oncology treatments for pediatric patients.

Future Directions at TransCode

Joining TransCode at this juncture is an exciting opportunity for Dr. Janicot. He expressed enthusiasm about the company's vision and commitment to advancing its pioneering RNA therapeutic pipeline. This role will enable him to steer key strategic initiatives that align with the company's objectives.

Leadership Strengthening TransCode’s Growth

Dr. Janicot's role as Senior Development Officer will involve not only supporting R&D strategies but actively contributing to the overall clinical development framework for TransCode's upcoming therapeutics, which are poised to enter late-stage clinical trials. His proven track record will be a cornerstone for the company as it seeks to bolster its market position and foster innovative treatments in oncology.

About TransCode Therapeutics

TransCode Therapeutics is dedicated to revolutionizing cancer treatment through cutting-edge research and development. The company's lead candidate, TTX-MC138, is designed to target metastatic tumors marked by the microRNA-10b biomarker. In addition, TransCode boasts a portfolio of innovative therapeutic candidates aimed at optimizing immune responses to eliminate cancer cells.

Frequently Asked Questions

1. Who is Dr. Michel Janicot?

Dr. Michel Janicot is a seasoned drug development professional and the newly appointed Senior Development Officer at TransCode Therapeutics.

2. What is TransCode Therapeutics focused on?

TransCode Therapeutics specializes in immuno-oncology and targeted therapies aimed at treating advanced cancers.

3. What are TTX-MC138 and Seviprotimut-L?

TTX-MC138 and Seviprotimut-L are TransCode's lead therapeutic candidates targeting metastatic and recurrent cancers.

4. What experience does Dr. Janicot bring to TransCode?

Dr. Janicot has over 35 years of experience in drug development, particularly in the oncology sector, having held senior positions at leading pharmaceutical companies.

5. How will Dr. Janicot impact TransCode’s projects?

His leadership and expertise will guide the strategic direction of TransCode’s oncology pipeline and contribute significantly to its drug development strategies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 165

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 98

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 126

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 165

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Trua: Veteran-Led Service Offers Senior Living Help

Updated Category News Views 31

A New Chapter for Senior Living Guidance Life's complexities can be as tough as a two-dollar steak, and let's face it, senior living decisions often top that chart. Greater Boston gets a new lifeline with Trua of Greater Boston breaking into the scene. Not just any placement service, mind you. Run by Jersouk Touy and Jessie Marasco, it promises a blend of personalized,...

Continue Reading
Standex International Corporation Reports Q4 Fiscal 2025 Results

Updated Category News Views 162

Standex International Corporation to Announce Q4 2025 Results Standex International Corporation (NYSE: SXI) is set to unveil its financial results for the fourth quarter of fiscal year 2025 on Thursday. The report will be released after the market closes, providing investors and stakeholders with key insights into the company's performance. Key Details of the Announcement...

Continue Reading
Ireland's €3 Billion Bond Sale Highlights Strong Investor Demand

Updated Category News Views 136

Overview of Ireland's Successful Bond Issuance Dublin has recently seen an impressive move in the financial markets with the National Treasury Management Agency successfully issuing €3 billion in 30-year fixed-rate notes. This significant bond issuance demonstrates the strong appetite from investors without the need for stabilization measures, reflecting confidence in...

Continue Reading
Exciting Developments in Yukon Metals' Birch Copper-Gold Project

Updated Category News Views 196

Significant Updates from the Birch Copper-Gold Project Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) has recently announced thrilling developments concerning its 100%-owned Birch Copper-Gold Project, spanning 7,000 hectares. This project is located approximately 65 kilometres from Burwash Landing and 200 kilometres from Whitehorse. The current drill program aims...

Continue Reading
Krystal Biotech's Upcoming Presentation at Major Healthcare Event

Updated Category News Views 122

Krystal Biotech Set to Attend Major Healthcare Conference Krystal Biotech, Inc. (NASDAQ: KRYS), a company dedicated to leading the way in genetic medicine, has shared an exciting opportunity for both investors and the public. The Company will highlight its latest advancements at the upcoming 2024 Cantor Global Healthcare Conference in New York. This event stands out as...

Continue Reading